BioMedNewsBreaks – BioMedWire to Serve as Official Newswire for FWD Pharma Conference and Strategic HCP Partnerships Summit

BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of many brands part of the InvestorBrandNetwork (“IBN”), today announced its collaboration with the FWD Pharma Conference, scheduled to be held Aug. 31-Sept. 1, 2020, as well as participation in the Strategic HCP Partnerships Summit, slated for Nov. 18-20, 2020. According to the update, IBN will serve as the official media sponsor and BioMedWire will serve as the official newswire of both events. “We have enjoyed working with the Global Strategic Management Institute on multiple events in the past and are looking forward to continuing that relationship,” Jonathan Keim, communications director for InvestorBrandNetwork, stated in the news release. “FWD Pharma has an impressive approach to joining industry professionals with interactive panels, case studies and hands-on workshops to help attendees truly understand the importance of today’s digital journey.”

To view the full press release, visit http://ibn.fm/as1PU

About The FWD Pharma Conference

The second annual FWD Pharma is designed to position professionals in the biotech, life sciences, and pharmaceutical industries for success. The three-day, forward-thinking virtual event will educate industry executives on how their organizations can benefit from digital technologies that are reducing costs, improving understanding of market dynamics and strengthening customer loyalty. Hosted by the Lincoln Health Network, the FWD Pharma virtual event is set for Aug. 3–Sept. 1, 2020. For more information, visit www.FWDPharmaConference.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Forms Strategic Consulting Partnership With PBACO Holding

HealthLynked (OTCQB: HLYK) announced a strategic consulting partnership with PBACO Holding LLC, a physician-led, value-based care organization…

4 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced it has opened research access to PDAOAI, its proprietary evidence interrogation platform designed to…

5 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to…

1 week ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease 

Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the…

1 week ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development

Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons…

1 week ago

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet…

1 week ago